In this episode, Kyle and Joe interview Mike Margolies of Psychedelic Seminars. In the show, they cover topics including guests and conversations from the Psychedelic Seminars, the decriminalization of all drugs, and the importance of allowing psychedelic use to be a part of training therapists for psychedelic therapy.
Since 2015, Mark has worked full-time in the psychedelic community, starting and contributing to a number of projects as an event and media producer, connector, and advisor. He is the Founder of Psychedelic Seminars, an educational conversation series deepening awareness of the benefits, risks, and complexities of psychedelics. On the PsychSems stage, he has interviewed a range of leaders including bestselling author Michael Pollan, Dr. James Fadiman and Ayelet Waldman on microdosing, and therapeutic ketamine expert Dr. Raquel Bennett. He started the project in 2015 after returning to his home city of Baltimore to build community for open and honest conversations about psychedelics. The project now operates primarily out of the San Francisco Bay Area and livestreams globally. Through his psychedelic community work in Baltimore, he seeded the Baltimore Psychedelic Society. He has sparked and mentored similar Psychedelic Societies around the world from Washington DC to San Francisco to Portugal. He helped start the Global Psychedelic Network to connect them.audibletrial.com/psychedelicstoday
In this Episode, Kyle sits down with Elizabeth Nielson and Ingmar Gorman, Co-founders of Fluence, Training in Psychedelic Integration. They are both therapists on the MAPS clinical trial for MDMA Assisted Psychotherapy for PTSD.
Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Dr. Ingmar Gorman is a co-founder of Fluence and a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.
In this episode, Joe interviews Jon S. on his experience in the psilocybin-assisted trials for alcohol dependency at NYU. In the show, they dive into Jon’s background and how psilocybin assisted therapy helped him out of his alcohol dependence and into a new life.
The sessions helped him so much with this dependence on alcohol, he believes he is a better father, husband, and human overall. He hasn't had a drink in 5 months (or a desire to).
In this episode, Joe interviews Joost Breeksema from the Netherlands to talk about the Interdisciplinary Conference on Psychedelic Research. In the show they cover topics on ICPR 2020, and the importance of accessibility.
Joost Breeksema is a part of the OPEN Foundation, which from it came the Interdisciplinary Conference on Psychedelic Research. His current research focuses on the experiences of patients that are undergoing therapy assisted by psychedelic substances. His aim is to better understand psychological mechanisms of action/change, to tease out salient themes, and finally to learn about what works and what does not work in psychedelic-assisted psychotherapy.Use code PSYTODAY at Onnit for a discount on all products except fitness equipment